TELA Bio Reports Q3 2026 Revenue Decline Amid Strategic Cost Reduction Initiatives
TELA Bio (TELA) reported a third-quarter revenue of $19 million, marking an 8% year-over-year decrease. The decline was primarily driven by a 20% drop in OviTex PRS revenue due to surgeon turnover and practice changes. Despite the top-line contraction, international revenue grew 18%, bolstered by complex cases in the United Kingdom, and the LIQUIFIX product line achieved record quarterly sales with a 60% year-to-date expansion in its customer base. To preserve capital and extend its cash runway into 2028, management has implemented a strategic cost reduction initiative aimed at $17 million in annualized savings. This plan includes a 20% headcount reduction and a realignment of the global sales force to focus on high-growth areas. While the company reported a net loss of $9.3 million, adjusted EBITDA losses improved by 55% sequentially due to a leaner cost structure.
Topics: cost reduction ebitda loss layoffs liquifix growth revenue decline